📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
1 articles
AVG GRADE
NEUTRAL
score: 0.00
SENTIMENT
BULLISH
TOTAL VIEWS
1
1-DAY GRADE TIMELINE
2026-06-11
TODAY
RECENT COVERAGE · 15 ARTICLES
AbbVie shares fell after six-session winning streak
ABBV terminated a six-session rally with a notable reversal, signaling potential profit-taking after a sustained uptrend. The breakdown...
AbbVie shares fell after six-session winning streak (NYSE:ABBV)
ABBV reversed course following a six-session advance, signaling profit-taking behavior after elevated momentum. The pullback arrives...
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?
AbbVie (ABBV) has achieved a new 52-week high following a substantial 130% appreciation over the past five years, prompting a valuation...
Lilly, J&J, AbbVie hit all-time highs (LLY:NYSE)
Three large-cap Health Care names—Eli Lilly (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV)—have reached new 52-week highs, signaling...
12 Most Profitable S&P 500 Stocks to Invest In
This article examines shifts in investor focus toward profitability metrics and capital efficiency as selection criteria for S&P 500...
Definium's Phase 3 LSD Depression Data Stuns the Tape as AbbVie Spends $10.9 Billion on Apogee
Definium's Phase 3 trial success in treating depression with LSD represents a potential therapeutic breakthrough in the psychedelic...
AbbVie Inc. (ABBV) Apogee Therapeutics, Inc. - M&A Call - Slideshow (NYSE:ABBV) 2026-06-23
AbbVie Inc. (ABBV) has disclosed a material M&A transaction involving Apogee Therapeutics, Inc., signaling strategic portfolio expansion...
AbbVie Inc. (ABBV) M&A Call Transcript
AbbVie (ABBV) hosted an M&A-focused investor call on June 22, 2026, signaling active capital allocation strategy and strategic portfolio...
Monday's Deal Table: AbbVie Buys Apogee for $10.9 Billion and CRH Takes Arcosa for $8.5 Billion, Both All-Cash
ABBV and CRH announced concurrent all-cash acquisition sprees totaling $19.4 billion, signaling aggressive M&A appetite among large-cap...
Markets Edge Higher as Two Big All-Cash Deals Land and the AI-Memory Trade Heats Up
AbbVie and CRH announced dual all-cash acquisitions totaling $19.4 billion, signaling continued M&A appetite despite macro...
AbbVie to acquire Apogee Therapeutics in $10.9B deal
AbbVie's $10.9 billion all-cash acquisition of Apogee Therapeutics represents a significant pipeline expansion in high-growth...
AbbVie To Acquire Immunology Drug Maker Apogee For $10.9 Bln Cash; Shares Climb
AbbVie's $10.9 billion acquisition of Apogee Therapeutics represents a strategic consolidation in the immunology and inflammatory...
The Club's top 10 things to watch in the stock market Monday
AbbVie (ABBV) is executing on its M&A strategy, signaling continued portfolio consolidation within the pharmaceutical sector. This move...
REGENXBIO’s Duchenne Data Keeps Me Bullish, But There’s Less Room For Setbacks Now (RGNX)
RGNX continues to demonstrate clinical momentum in its gene therapy pipeline, particularly with RGX-202 advancing through Phase 3 trials...
5 Dividend Stocks to Buy and Hold Forever
This article presents a thematic investment strategy centered on dividend-yielding equities as vehicles for long-term wealth...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice